Dear My Parkinson's Info Reader,
We have been eagerly anticipating the launch of SCHWARZ PHARMA's new product—Neupro® (Rotigotine Transdermal System)—since it was approved last month by the U.S. Food and Drug Administration (FDA) for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease.
My Parkinson's Info has received thousands of requests for information about Neupro. Like you, we look forward to the launch of Neupro later this summer. If you requested information through our Web site, you can expect SCHWARZ PHARMA to send it within the next two months.
You might be wondering about the wait from the time the FDA approves the drug until its launch. Currently, SCHWARZ PHARMA is working with the FDA to refine the Neupro product literature. Together they will determine the most appropriate way to describe the use, benefits, and risks associated with Neupro. This process must be complete before the product can be distributed in the United States.
As you have read in the My Parkinson's Info newsletters, Neupro is a dopamine receptor-agonist formulated as a patch. The system is applied to the skin once a day and provides rotigotine continuously to the body for 24 hours. Rotigotine is designed to mimic the action of dopamine, a naturally produced neurotransmitter crucial for proper motor functioning.
We encourage you to learn more about Neupro. If you think it could provide you with additional health benefits, check with the doctor who helps you manage Parkinson's disease.
Sincerely,
Matt Nilsen, Editor My Parkinson's Info mnilsen@myparkinsonsinfo.com
